|Application ||WB, IHC, FC, IP, E|
|Other Names||Myc proto-oncogene protein, Class E basic helix-loop-helix protein 39, bHLHe39, Proto-oncogene c-Myc, Transcription factor p64, MYC, BHLHE39|
|Target/Specificity||A synthetic peptide, corresponding to aa 408-439 (AEEQKLISEEDLLRKRREQLKHKLEQL-RNSCA) from C-terminus of human c-myc, coupled to KLH|
|Application Note||ELISA : For coating, order Ab without BSA|
Flow Cytometry : 0.5-1ug/million cells
Immunofluorescence : 1-2ug/ml
Western Blotting : 0.5-1.0 µg/ml
Immunoprecipitation : 1-2ug/500ug protein lysate
Immunohistology (Frozen Only) : 0.5-1.0 µg/ml for 30 minutes at RT.
|Format||0.5 ml at 200ug/ml with BSA and azide|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||c-Myc Oncoprotein Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Transcription factor that binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'- CAC[GA]TG-3'. Activates the transcription of growth-related genes.|
|Cellular Location||Nucleus, nucleoplasm. Nucleus, nucleolus|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The c-Myc protein is a transcription factor, which is encoded by the c-Myc gene on human chromosome 8q24. c-Myc is commonly activated in a variety of tumor cells and plays an important role in cellular proliferation, differentiation, apoptosis and cell cycle progression. The phosphorylation of c-Myc has been investigated and previous studies have suggested a functional association between phosphorylation at Thr58/Ser62 by glycogen synthase kinase 3, cyclin dependent kinase, ERK2 and C-Jun N terminal Kinase (JNK) in cell proliferation and cell cycle regulation. Studies also have shown that c-Myc is essential for tumor cell development in vasculogenesis and angiogenesis that distribute blood throughout the cells, and which brought extensive attention in the development of new therapeutic approach for cancer treatment.
1. Evan GI, et. al. Molecular and Cellular Biology, 1985, 5(12):3610-6.
If you have any additional inquiries please email technical services at email@example.com.